AKBM: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER

February 21, 2025 – Trond Atle Smedsrud, CEO Emerging Business, Aker BioMarine, purchased 6000 shares in Aker BioMarine ASA at an average price of NOK 66 per share on February 21 through his wholly-owned investment company Hawi Holding AS. The shares were acquired on Oslo Børs. Following the transaction, Smedsrud holds a total of 10 410 shares in Aker BioMarine ASA. For further information, please contact Christopher Robin Vinter, VP Strategic Finance & IR Mobile: +47 911 60 820 Email: Christopher.vinter@akerbiomarine.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. About Aker BioMarine: Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.